NASDAQ:PTX - Pernix Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.81 -0.04 (-4.71 %) (As of 09/20/2018 12:25 PM ET)Previous Close$0.81Today's Range$0.81 - $0.8452-Week Range$0.79 - $3.35Volume600 shsAverage Volume285,873 shsMarket Capitalization$12.50 millionP/E RatioN/ADividend YieldN/ABeta1.33 Company ProfileDiscussionChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs primarily for the United States market. It targets underserved therapeutic areas, such as central nervous system (CNS), including pain, neurology, and psychiatry. The company's products comprise Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; Silenor, a non-narcotic, non-scheduled, and non-addictive prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance; and Treximet, a fixed dose combination product indicated for the treatment of acute migraine. Pernix Therapeutics Holdings, Inc. markets and sells its non-core products, including generics through its wholly owned subsidiaries; and markets its non-promoted products through distributors and trade partners. It serves drug wholesalers, specialty pharmacies, retail drug stores, mass merchandisers, and grocery store pharmacies. Pernix Therapeutics Holdings, Inc. was founded in 1996 and is headquartered in Morristown, New Jersey. Receive PTX News and Ratings via Email Sign-up to receive the latest news and ratings for PTX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical SymbolNASDAQ:PTX CUSIP71426V10 Webwww.pernixtx.com Phone800-793-2145 Debt Debt-to-Equity Ratio-1.37 Current Ratio0.77 Quick Ratio0.71 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$146.07 million Price / Sales0.08 Cash FlowN/A Price / CashN/A Book Value($14.77) per share Price / Book-0.05 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-77,140,000.00 Net Margins-44.32% Return on EquityN/A Return on Assets-37.62% Miscellaneous Employees171 Outstanding Shares13,920,000Market Cap$12.50 million Pernix Therapeutics (NASDAQ:PTX) Frequently Asked Questions What is Pernix Therapeutics' stock symbol? Pernix Therapeutics trades on the NASDAQ under the ticker symbol "PTX." How were Pernix Therapeutics' earnings last quarter? Pernix Therapeutics Holdings Inc (NASDAQ:PTX) issued its quarterly earnings data on Thursday, August, 9th. The specialty pharmaceutical company reported ($1.13) EPS for the quarter. The specialty pharmaceutical company earned $21.09 million during the quarter. View Pernix Therapeutics' Earnings History. When is Pernix Therapeutics' next earnings date? Pernix Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for Pernix Therapeutics. Who are some of Pernix Therapeutics' key competitors? Some companies that are related to Pernix Therapeutics include VIVUS (VVUS), Acerus Pharmaceuticals (TRLPF), Aileron Therapeutics (ALRN), Vascular Biogenics (VBLT), Zosano Pharma (ZSAN), Eyenovia (EYEN), Novus Therapeutics (NVUS), AzurRx BioPharma (AZRX), Moleculin Biotech (MBRX), Heat Biologics (HTBX), Onconova Therapeutics (ONTX), Advaxis (ADXS), Nemus Bioscience (NMUS), Addex Therapeutics (ADDXF) and PLx Pharma (PLXP). Who are Pernix Therapeutics' key executives? Pernix Therapeutics' management team includes the folowing people: Mr. John Anthony Sedor, Chairman & CEO (Age 73)Mr. Kenneth R. Pina Esq., Sr. VP, Chief Legal & Compliance Officer and Corp. Sec. (Age 59)Mr. Angus W. Smith, Sr. VP, Chief Bus. Officer & Principal Financial Officer (Age 35)Mr. Glenn Whaley, Principal Accounting Officer, VP of Fin. & Corp. Controller (Age 50)Mr. Anthony M. Orrico, VP of Technical & Supply Operations Has Pernix Therapeutics been receiving favorable news coverage? Headlines about PTX stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pernix Therapeutics earned a media and rumor sentiment score of 0.18 on Accern's scale. They also assigned media stories about the specialty pharmaceutical company an impact score of 46.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for Pernix Therapeutics. How do I buy shares of Pernix Therapeutics? Shares of PTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Pernix Therapeutics' stock price today? One share of PTX stock can currently be purchased for approximately $0.81. How big of a company is Pernix Therapeutics? Pernix Therapeutics has a market capitalization of $12.50 million and generates $146.07 million in revenue each year. Pernix Therapeutics employs 171 workers across the globe. How can I contact Pernix Therapeutics? Pernix Therapeutics' mailing address is 10 NORTH PARK PLACE SUITE 201, MORRISTOWN NJ, 07960. The specialty pharmaceutical company can be reached via phone at 800-793-2145 or via email at [email protected] MarketBeat Community Rating for Pernix Therapeutics (NASDAQ PTX)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 306 (Vote Outperform)Underperform Votes: 196 (Vote Underperform)Total Votes: 502MarketBeat's community ratings are surveys of what our community members think about Pernix Therapeutics and other stocks. Vote "Outperform" if you believe PTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/20/2018 by MarketBeat.com StaffFeatured Article: Do Tariffs Work?